Invitro antibiotic susceptibility profile of Clostridium difficile excluding PCR ribotype 027 outbreak strain in Hungary

Anaerobe

Volumn 30, Issue , 2014, Pages 41-44

  Terhes, Gabriella ^a   Maruyama, Akiko ^a   Latkóczy, Krisztina ^b   Szikra, Lenke ^c   Konkoly Thege, Marianne ^d   Princz, Gyula ^d   Nagy, Elisabeth ^a   Urbán, Edit ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Cyclolab   (Hungary)

^c Laboratory Ltd   (Hungary)

^d Szent Laszlo Hospital   (Hungary)

Author keywords

Antibiotic; Clostridium difficile; Diarrhoea; Resistance; Susceptibility

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; METRONIDAZOLE; MOXIFLOXACIN; RIFAMPICIN; ANTIINFECTIVE AGENT; LINCOSAMIDE; MACROLIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; CDTA GENE; CDTB GENE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; EPSILOMETER TEST; HUNGARY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RIBOTYPING; TCDA GENE; TCDB GENE; CLASSIFICATION; CLOSTRIDIUM INFECTION; COMMUNITY ACQUIRED INFECTION; CROSS INFECTION; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; FECES ANALYSIS; MIC50; MIC90; NOSOCOMIAL ACQUIRED CLOSTRIDIUM DIFFICILE INFECTION;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; HUNGARY; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; RIBOTYPING;

EID: 84906751715     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2014.08.005     Document Type: Article

References (21)

1. Weiss K., Bergeron L., Bernatchez H., Goyette M., Savoie M., Thirion D. Clostridium difficile-associated diarrhoea rates and global antibiotic consumption in five Quebec institutions from 2001 to 2004. Int J Antimicob Agents 2007, 30:309-314.
2. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. NEngl J Med 2005, 353:2442-2449.
3. Pépin J., Saheb N., Coulombe M.A., Alary M.E., Corriveau M.P., Authier S., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260.
4. Matuz M., Benko R., Hajdú E., Viola R., Soós G. Evaluation of ambulatory antibiotic use in Hungary using drug-specific quality indicators. Orv Hetil 2013, 154:947-956.
5. Kato H., Kato N., Watanabe K., Iwai N., Nakamura H., Yamamoto T., et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. JClin Microbiol 1998, 36:2178-2182.
6. Kato N., Chin-Yih Ou H., Kato S., Bartley V.K., Brown V.R., Dowell J.R., et al. Identification of toxigenic Clostridium difficile by the polymerase chain reaction. JClin Microbiol 1991, 29:33-37.
7. Stubbs S., Rupnik M., Gibert M., Brazier J., Duerden B., Popoff M. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of C.difficile. FEMS Microbiol Lett 2000, 186:307-312.
8. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. (2011) M100-S21 vol. 31 No. 1 ISBN 1-56238-742-1.
9. Ambler J., Rennie R., Poupard J., Koeth L., Stass H., Endermann R., et al. Determination of moxifloxacin anaerobic susceptibility breakpoints according to the clinical and laboratory standards institute guidelines. Diagn Microbiol Infect Dis 2008, 61:49-57.
10. The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1 2013, http://www.eucast.org.
11. Terhes G., Urbán E., Sóki J., Szikra L., Konkoly-Thege M., Vollain M., et al. Assessment of changes in the epidemiology of Clostridium difficile isolated from diarrhoeal patients in Hungary. Anaerobe 2009, 15:237-240.
12. Peláez T., Alcalá L., Alonso R., Rodriguez-Creixems M., García-Lechuz J., Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002, 46:1647-1650.
13. Peláez T., Cercenado E., Alcalá L., Marín M., Martín-López A., Martínez-Alarcón J., et al. Metronidazole resistance in Clostridium difficile is heterogeneous. JClin Microbiol 2008, 46:3028-3032.
14. Brazier J.S., Fawley W., Freeman J., Wilcox M. Reduced susceptibility of Clostridium difficile to metronidazole. JAntimicrob Chemother 2001, 48:741-742.
15. Baines S.D., O'Connor R., Freeman J., Fawley W.N., Harmanus C., Mastrantonio P., et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. JAntimicrob Chemother 2008, 62:1046-1052.
16. Aspevall O., Lundberg A., Burman L.G., Akerlund T., Svenungsson B. Antimicrobial susceptibility pattern of Clostridum difficile and its relation to PCR ribotypes in a Swedish University Hospital. Antimicrob Ag Chemother 2006, 50:1890-1892.
17. Spigaglia P., Barbanti F., Mastrantonio P. Multidrug resistance in European Clostridium difficile clinical isolates. JAntimicrob Chemother 2011, 66:2227-2234. on behalf of the European Study Group on Clostridium difficile (ESGCD).
18. Lynch T., Chong P., Zhang J., Hizon R., Du R., Graham M.R., et al. Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate. PLOS One 2013, 8:e53757.
19. Huang H., Weintraub A., Fang H., Nord C.E. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 2009, 34:516-522.
20. Mutlu E., Wroe A.J., Sanchez-Hurtado K., Brazier J.S., Poxton I.R. Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. JMed Microbiol 2007, 56:921-929.
21. O'Connor J.R., Galang M.A., Sambol S.P., Hecht D.W., Vedantam G., Gerding D.N., et al. Rifampin and rifaximin resisitance in clinical isolates of Clostridium difficile. Antimicrob Ag Chemother 2008, 52:2813-2817.